Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes: a pilot study

Current Vascular Pharmacology
Munehisa BekkiSho-ichi Yamagishi

Abstract

We have found that anagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4) significantly ameliorates arterial stiffness in type 2 diabetes mellitus (T2DM) patients compared with an equivalent hypoglycaemic agent, glimepiride. However, it remains unclear whether switching DPP-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) improves arterial stiffness in T2DM patients. Nineteen T2DM patients who had received DPP-4 inhibitors for at least 1 year were enrolled in this study. Clinical parameters and arterial stiffness evaluated by cardio-ankle vascular index (CAVI) were measured at baseline and after 6-months treatment with tofogliflozin. At 6 months after switching to tofogliflozin, CAVI, waist circumference, body weight, body mass index, subcutaneous and visceral fat volume, white blood cell number, fasting plasma insulin, uric acid, aspartate transaminase (AST), -glutamyl transferase (GTP), and advanced glycation end products (AGEs) were significantly reduced, while red blood cell number, haemoglobin, and HbA1c values were increased. When stratified by median values of change in CAVI after switching to tofogliflozin (∆CAVI), baseline serum levels of AGEs were significantly higher in ...Continue Reading

References

Oct 21, 2005·The International Journal of Biochemistry & Cell Biology·Bulent O Yildiz, Ibrahim C Haznedaroglu
Aug 4, 2007·Kidney International. Supplement·Y J LeeH J Han
May 6, 2008·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Yong-Jae LeeJae-Yong Shim
Dec 17, 2008·Pharmacological Reviews·Wook Kim, Josephine M Egan
Dec 8, 2009·Clinical Journal of the American Society of Nephrology : CJASN·René Santer, Joaquim Calado
Feb 16, 2011·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Takanori MatsuiSho-ichi Yamagishi
Dec 30, 2011·Current Pharmaceutical Design·Sho-ichi Yamagishi, Takanori Matsui
May 15, 2013·Integrated Blood Pressure Control·Cheuk-Kwan Sun
Jul 13, 2013·Current Pharmaceutical Design·Hideyuki HyogoSho-Ichi Yamagishi
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Jul 11, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Kenichiro OtsukaJunichi Yoshikawa
Dec 30, 2014·Journal of the American Society of Hypertension : JASH·George Maliha, Raymond R Townsend
Feb 11, 2015·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Zhi Xiao LuoQian Ge
Feb 20, 2015·The Journal of Clinical Endocrinology and Metabolism·Nobuhiro TaharaYoshihiro Fukumoto
May 30, 2015·Diabetology & Metabolic Syndrome·Nobutaka NakamuraSho-Ichi Yamagishi
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jun 17, 2015·World Journal of Gastroenterology : WJG·Vasilios G AthyrosDimitri P Mikhailidis
Aug 1, 2015·Rejuvenation Research·Sho-ichi Yamagishi, Takanori Matsui
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Nov 18, 2015·Current Opinion in Nephrology and Hypertension·Aleksandra Novikov, Volker Vallon
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jun 17, 2016·Current Medical Research and Opinion·Niki KatsikiDimitri P Mikhailidis
Jan 17, 2017·Current Pharmaceutical Design·Niki KatsikiMichael J Theodorakis

❮ Previous
Next ❯

Citations

Aug 2, 2019·Circulation Journal : Official Journal of the Japanese Circulation Society·Sho-Ichi Yamagishi
Mar 12, 2019·Mini Reviews in Medicinal Chemistry·Sho-Ichi YamagishiTakanori Matsui
Jul 1, 2020·Journal of Atherosclerosis and Thrombosis·Atsuhito SaikiIchiro Tatsuno
Jul 6, 2018·Current Hypertension Reports·Korshie DumorAdam Whaley-Connell
Jun 11, 2020·Journal of Clinical Medicine·Pilar SanchisLuis Masmiquel
Feb 9, 2021·Therapeutic Advances in Endocrinology and Metabolism·Joanna M BilakGerry P McCann
Mar 2, 2021·Frontiers in Cardiovascular Medicine·Qingchun ZengDingli Xu
Aug 17, 2021·Journal of cardiology·Toru Miyoshi, Hiroshi Ito

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.